Alcanza Clinical Research, a mission-focused investigator site network, announces the acquisition of Kansas City Research Institute (KCRI), a Phase II-IV clinical research site based in Kansas City, MO, with therapeutic specializations focused in gastroenterology, gastrointestinal oncology, hepatology, and a host of metabolic diseases (metabolic associated steatohepatitis [MASH], obesity, type 2 diabetes, hyperlipidemia). “With the addition of KCRI, Alcanza is one step closer to our goal of making clinical research accessible for all, by enabling us to offer more trial participation opportunities to patients who are not traditionally represented in clinical research, especially with diseases and chronic indications that disproportionately impact those same patient populations,” said Carlos Orantes, CEO of Alcanza.
Read the full article: Alcanza Strengthens Midwest Presence with Acquisition of Kansas City Research Institute //
Source: https://www.prnewswire.com/news-releases/alcanza-strengthens-midwest-presence-with-acquisition-of-kansas-city-research-institute-302133208.html